Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 3.31
AGEN's Cash-to-Debt is ranked lower than
64% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. AGEN: 3.31 )
Ranked among companies with meaningful Cash-to-Debt only.
AGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24  Med: 1.39 Max: 372.03
Current: 3.31
0.24
372.03
Equity-to-Asset -0.85
AGEN's Equity-to-Asset is ranked lower than
97% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AGEN: -0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
AGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.33  Med: -0.1 Max: 0.92
Current: -0.85
-1.33
0.92
Debt-to-Equity -0.12
AGEN's Debt-to-Equity is ranked lower than
99.99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. AGEN: -0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
AGEN' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.93  Med: 0 Max: 16.81
Current: -0.12
-7.93
16.81
Debt-to-EBITDA -0.11
AGEN's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. AGEN: -0.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AGEN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.17  Med: -1.77 Max: -0.11
Current: -0.11
-7.17
-0.11
Piotroski F-Score: 2
Altman Z-Score: -14.03
Beneish M-Score: -0.53
WACC vs ROIC
16.77%
274.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -417.54
AGEN's Operating Margin % is ranked lower than
73% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. AGEN: -417.54 )
Ranked among companies with meaningful Operating Margin % only.
AGEN' s Operating Margin % Range Over the Past 10 Years
Min: -1427.54  Med: -586.16 Max: -42.23
Current: -417.54
-1427.54
-42.23
Net Margin % -515.28
AGEN's Net Margin % is ranked lower than
75% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. AGEN: -515.28 )
Ranked among companies with meaningful Net Margin % only.
AGEN' s Net Margin % Range Over the Past 10 Years
Min: -1161.86  Med: -630.45 Max: -70.95
Current: -515.28
-1161.86
-70.95
ROA % -103.65
AGEN's ROA % is ranked lower than
85% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AGEN: -103.65 )
Ranked among companies with meaningful ROA % only.
AGEN' s ROA % Range Over the Past 10 Years
Min: -103.65  Med: -62.2 Max: -46.32
Current: -103.65
-103.65
-46.32
ROC (Joel Greenblatt) % -464.81
AGEN's ROC (Joel Greenblatt) % is ranked higher than
50% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. AGEN: -464.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -926.73  Med: -391.04 Max: -196.65
Current: -464.81
-926.73
-196.65
3-Year Revenue Growth Rate 55.00
AGEN's 3-Year Revenue Growth Rate is ranked higher than
90% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AGEN: 55.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.9  Med: 3.35 Max: 96.1
Current: 55
-53.9
96.1
3-Year EBITDA Growth Rate -20.50
AGEN's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. AGEN: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.2  Med: 6.6 Max: 50.9
Current: -20.5
-63.2
50.9
3-Year EPS without NRI Growth Rate -20.10
AGEN's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. AGEN: -20.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 14 Max: 39.7
Current: -20.1
-30.1
39.7
GuruFocus has detected 5 Warning Signs with Agenus Inc AGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGEN's 30-Y Financials

Financials (Next Earnings Date: 2018-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AGEN Guru Trades in Q3 2017

Ken Fisher 192,900 sh (+42.67%)
Robert Bruce 155,677 sh (unchged)
Jim Simons Sold Out
» More
Q4 2017

AGEN Guru Trades in Q4 2017

Ken Fisher 258,170 sh (+33.84%)
Robert Bruce 155,677 sh (unchged)
» More
Q1 2018

AGEN Guru Trades in Q1 2018

Steven Cohen 3,469,613 sh (New)
Jim Simons 1,882,815 sh (New)
Ken Fisher 269,170 sh (+4.26%)
Robert Bruce Sold Out
» More
Q2 2018

AGEN Guru Trades in Q2 2018

Paul Tudor Jones 19,066 sh (New)
Steven Cohen Sold Out
Jim Simons 934,315 sh (-50.38%)
Ken Fisher 11,000 sh (-95.91%)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -95.91%$2.26 - $4.65 $ 1.87-46%11,000
Ken Fisher 2018-03-31 Add 4.26%$3.51 - $6.04 $ 1.87-59%269,170
Robert Bruce 2018-03-31 Sold Out 0.12%$3.51 - $6.04 $ 1.87-59%0
Ken Fisher 2017-12-31 Add 33.84%$3.26 - $4.78 $ 1.87-52%258,170
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Agenus Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:LSE:ARIX, XKRX:228760, XPAR:VLA, NAS:ALBO, NAS:CRBP, SHSE:603139, TSE:2183, ASX:VLA, XBRU:CYAD, XTER:MDG1, LSE:FARN, NAS:QTRX, NAS:DERM, NAS:GTXI, NAS:KALA, NAS:CORI, TSE:4563, XPAR:ERYP, NAS:MRUS, NAS:CLSD » details
Traded in other countries:AJ81.Germany,
Headquarter Location:USA
Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Agenus Inc is an American biotechnology company. Its main target are immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs.

Ratios

vs
industry
vs
history
PS Ratio 6.58
AGEN's PS Ratio is ranked higher than
53% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AGEN: 6.58 )
Ranked among companies with meaningful PS Ratio only.
AGEN' s PS Ratio Range Over the Past 10 Years
Min: 4.6  Med: 19.87 Max: 56.28
Current: 6.58
4.6
56.28
EV-to-EBIT -1.48
AGEN's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AGEN: -1.48 )
Ranked among companies with meaningful EV-to-EBIT only.
AGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.6  Med: -4.7 Max: -1.2
Current: -1.48
-26.6
-1.2
EV-to-EBITDA -1.56
AGEN's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AGEN: -1.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.9  Med: -5 Max: -1.2
Current: -1.56
-41.9
-1.2
EV-to-Revenue 6.20
AGEN's EV-to-Revenue is ranked higher than
57% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AGEN: 6.20 )
Ranked among companies with meaningful EV-to-Revenue only.
AGEN' s EV-to-Revenue Range Over the Past 10 Years
Min: 5  Med: 25.7 Max: 64.4
Current: 6.2
5
64.4
Current Ratio 1.32
AGEN's Current Ratio is ranked lower than
74% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AGEN: 1.32 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.66 Max: 42.49
Current: 1.32
0.64
42.49
Quick Ratio 1.32
AGEN's Quick Ratio is ranked lower than
69% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AGEN: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.64 Max: 42.49
Current: 1.32
0.64
42.49
Days Sales Outstanding 136.29
AGEN's Days Sales Outstanding is ranked higher than
82% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AGEN: 136.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.12  Med: 12.62 Max: 183.56
Current: 136.29
0.12
183.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.50
AGEN's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AGEN: -17.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -20.1 Max: -1.5
Current: -17.5
-52
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.33
AGEN's Price-to-Median-PS-Value is ranked higher than
77% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AGEN: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.52 Max: 141.75
Current: 0.33
0.29
141.75
Earnings Yield (Greenblatt) % -67.27
AGEN's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AGEN: -67.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -84.2  Med: -21.3 Max: -3.8
Current: -67.27
-84.2
-3.8

More Statistics

Revenue (TTM) (Mil) $29.24
EPS (TTM) $ -1.49
Beta2.70
Volatility79.46%
52-Week Range $1.55 - 6.19
Shares Outstanding (Mil)113.28

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 20 20 73
EBIT (Mil $) -129 -132 -82
EBITDA (Mil $)
EPS ($) -1.40 -1.32 -0.75
EPS without NRI ($) -1.40 -1.32 -0.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}